Aardvark Therapeutics, Inc. - 10-Q Filing

Aardvark Therapeutics reports Q3 2026 net loss as research and development expenses rise to $15.7M for the quarter.

SEC EDGAR · November 13, 2026, 11:05 UTC

Tickers: $AARD

More Regulatory news

Nova Minerals Corp - 8-K Filing SEC EDGAR · November 13, 2026, 11:45 UTC
Vertiv Holdings Co - 8-K Filing SEC EDGAR · November 13, 2026, 11:35 UTC
Rezolute, Inc. - 8-K Filing SEC EDGAR · November 13, 2026, 11:27 UTC
REGIONAL HEALTH PROPERTIES, INC - 10-Q Filing SEC EDGAR · November 13, 2026, 11:25 UTC
BLUE BIOFUELS, INC. - 10-Q Filing SEC EDGAR · November 13, 2026, 11:20 UTC
First Choice Healthcare Solutions, Inc. - 10-Q Filing SEC EDGAR · November 13, 2026, 11:19 UTC
OpenWorld, Inc. - 10-Q Filing SEC EDGAR · November 13, 2026, 11:04 UTC
NEKTAR THERAPEUTICS - 8-K Filing SEC EDGAR · November 13, 2026, 11:02 UTC
Weatherford International Corp - 8-K Filing SEC EDGAR · November 13, 2026, 11:04 UTC
iRhythm Holdings, Inc. - 8-K Filing SEC EDGAR · November 13, 2026, 11:00 UTC